COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
Resources from Association for the Health
Care Environment - AHE, American Society for Health
Care Engineers - ASHE, and Teamtraing
The Food and Drug Administration announced a Class 1 recall of two COVID-19 tests the agency had not authorized or approved.
Pfizer asked the Food and Drug Administration to authorize for emergency use two 3-microgram doses of its COVID-19 vaccine for children aged 6 months through 4.
Once the COVID-19 omicron variant became prominent through Jan. 8, unvaccinated adults in Los Angeles County had a 3.6 times higher SARS-CoV-2 infection rate and 23 times higher hospitalization rate than adults who had received a COVID-19 vaccine booster, the Centers for Disease Control and…
The Centers for Medicare & Medicaid Services’ (CMS) accelerated/advance payment program provides necessary funds when there are disruptions in claims submission and/or processing.
The Food and Drug Administration issued an update on the Class 1 recall of certain Philips Respironics ventilators.
The Food and Drug Administration granted full approval to the Moderna COVID-19 vaccine for individuals age 18 and older.
Get your point across quickly using the SBAR framework to help communicate quickly & concisely in any setting with this Project Firstline program.
Based on recent data on omicron variant susceptibility to monoclonal antibodies, the Food and Drug Administration revised its emergency use authorizations for the combination therapies bamlanivimab and etesevimab and REGEN-COV (casirivimab and imdevimab) to exclude geographic regions where the…
The Food and Drug Administration expanded the approved uses for Vekury (remdesivir) to include non-hospitalized patients aged 12 and older who test positive for SARS-CoV-2, weigh at least 88 pounds and are at high risk of progressing to severe COVID-19.